Liew Yu HengKhoo GideonLyn R. GriffithsLoo Keat Wei2024-12-262024-12-262024-10-0110.1088/1755-1315/1408/1/012014https://dspace-cris.utar.edu.my/handle/123456789/8186The coronavirus disease 2019 (COVID-19) has been circulating in the local and global population. Among the SARS-CoV-2 variants, the Omicron strain tends to be detected in the recent genomic surveillance studies. Despite being a manageable disease, recovered patients may experience post-COVID-19 conditions such as cough (50.6%), fatigue (45.8%), and memory loss (37.4%). While developing an updated vaccine for COVID-19 is time-consuming, the <i>in-silico</i> discovery of phytoconstituents that bind to the SARS-CoV-2 receptor binding domain (RBD), may provide insights on the potential of edible plants as complementary treatments. This study aimed to investigate and compare the ligand-protein interactions of phytoconstituents and COVID-19 treatment drug, remdesivir, to the SARS-CoV-2 spike protein. The molecular docking results indicated that kaempferol and luteolin could potentially mitigate COVID-19, as they exhibited higher RBD-binding affinities than remdesivir.proceedings-article